Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma | OncLive Tafasitamab plus lenalidomide and rituximab has been approved by the European Commission in relapsed/refractory follicular lymphoma.

Tafasitamab Plus Lenalidomide and Rituximab Nets #EuropeanApproval in R/R #FollicularLymphoma

www.onclive.com/view/tafasit...

Click Subscribe #HIVPrevention #GileadSciences #EuropeanApproval #Lenacapavir #PublicHealth